<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10487">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657709</url>
  </required_header>
  <id_info>
    <org_study_id>V72P13</org_study_id>
    <secondary_id>EUDRACT 2007-007781-38</secondary_id>
    <nct_id>NCT00657709</nct_id>
  </id_info>
  <brief_title>Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants</brief_title>
  <official_title>A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Austria: Federal Office for Safety in Health Care</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to
      lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with
      routine infant vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination</measure>
    <time_frame>one month after the third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)</measure>
    <time_frame>one month after the third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)</measure>
    <time_frame>1 month after the third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ</measure>
    <time_frame>1 Month after the third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)</measure>
    <time_frame>1 month after third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations</measure>
    <time_frame>1 month after third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Antibody Response Against the Routine Antigens</measure>
    <time_frame>1 Month after third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(&gt;=1:8). Diptheria and Tetanus: primary endpoint ELISA &gt;=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA&gt;=1.0 IU/mL.
HepB (HBV):primary endpoint ELISA &gt;=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC &gt;=0.35 mcg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination</measure>
    <time_frame>1 Month after third vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA Titers ≥1:8</measure>
    <time_frame>1 month after third vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine</measure>
    <time_frame>upto 7 days after any vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">3630</enrollment>
  <condition>Serogroup B Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>rMenB Lot1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rMenB Lot2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rMenB Lot3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenC + Routine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)</intervention_name>
    <description>One dose of rMenB Lot concomitantly with the routinely administered infant vaccines</description>
    <arm_group_label>rMenB Lot1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)</intervention_name>
    <description>One dose of rMenB concomitantly with the routinely administered infant vaccines</description>
    <arm_group_label>rMenB Lot2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)</intervention_name>
    <description>One dose of rMenB concomitantly with the routinely administered infant vaccines</description>
    <arm_group_label>rMenB Lot3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix Hexa</intervention_name>
    <description>Routine vaccination</description>
    <arm_group_label>Routine</arm_group_label>
    <arm_group_label>MenC + Routine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Menjugate</intervention_name>
    <description>One dose of the routinely administered infant vaccines + MenC vaccine</description>
    <arm_group_label>MenC + Routine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Routine vaccination</description>
    <arm_group_label>Routine</arm_group_label>
    <arm_group_label>MenC + Routine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month old infants (55-89 days, inclusive)

        Exclusion Criteria:

          -  Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis,
             Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens)

          -  Previous ascertained or suspected disease caused by N. meningitidis

          -  History of severe allergic reaction after previous vaccinations or hypersensitivity
             to any vaccine component;

          -  Any serious chronic or progressive disease

          -  Known or suspected impairment or alteration of the immune system
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grässl</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Häckel</name>
      <address>
        <city>Kirchdorf</city>
        <zip>4560</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prieler</name>
      <address>
        <city>Neufeld a.d. Leitha</city>
        <zip>2491</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maurer</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angermayr</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sommer</name>
      <address>
        <city>Wien</city>
        <zip>1230</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Boskovice</city>
        <zip>680 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Brno</city>
        <zip>628 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Chomutov</city>
        <zip>430 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Děčín</city>
        <zip>405 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Havlíčkův Brod</city>
        <zip>580 22</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Hranice I-mesto</city>
        <zip>753 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Humpolec</city>
        <zip>396 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Jindřichův Hradec</city>
        <zip>377 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Kladno 2</city>
        <zip>272 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Kolín</city>
        <zip>280 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Liberec</city>
        <zip>460 15</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Litomerice</city>
        <zip>412 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 68</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Plzeň</city>
        <zip>305 99</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Prague</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Prague</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Prague</city>
        <zip>16000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Prague</city>
        <zip>19000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Rumburk</city>
        <zip>408 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>400 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Znojmo</city>
        <zip>669 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site11</name>
      <address>
        <city>Červený Kostelec</city>
        <zip>54941</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>Kotka</city>
        <zip>48600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 99</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 92</name>
      <address>
        <city>Espelkamp</city>
        <zip>32339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 95</name>
      <address>
        <city>Freising</city>
        <zip>85354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58</name>
      <address>
        <city>Lauffen</city>
        <zip>74348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57</name>
      <address>
        <city>Marbach a. N.</city>
        <zip>74348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 97</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 96</name>
      <address>
        <city>München</city>
        <zip>81475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 91</name>
      <address>
        <city>Műnchen</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81</name>
      <address>
        <city>Porta Westfalica</city>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 65</name>
      <address>
        <city>Schwieberdingen</city>
        <zip>71701</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 94</name>
      <address>
        <city>Weilheim</city>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze della Salute</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Messina - Pad. NI - A.O.U. Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <zip>98122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Italia</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatria dell' Ospedale Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carita'-Clinica Pediatrica</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Igiene e Medicina Preventiva - Università degli Studi di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL/TA</name>
      <address>
        <city>Taranto</city>
        <zip>74100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 13, 2015</lastchanged_date>
  <firstreceived_date>April 2, 2008</firstreceived_date>
  <firstreceived_results_date>February 13, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infant</keyword>
  <keyword>Meningococcal disease</keyword>
  <keyword>prevention</keyword>
  <keyword>vaccination</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>16 sites in Finland, 28 sites in the Czech Republic, 13 sites in Germany, 6 sites in Austria, 7 sites in Italy.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>rMenB Lot1</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="P2">
          <title>rMenB Lot2</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="P3">
          <title>rMenB Lot3</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="P4">
          <title>Routine</title>
          <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
        </group>
        <group group_id="P5">
          <title>MenC+ Routine</title>
          <description>Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="833"/>
                <participants group_id="P2" count="828"/>
                <participants group_id="P3" count="820"/>
                <participants group_id="P4" count="659"/>
                <participants group_id="P5" count="490"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="810"/>
                <participants group_id="P2" count="795"/>
                <participants group_id="P3" count="792"/>
                <participants group_id="P4" count="645"/>
                <participants group_id="P5" count="457"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>AE or Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rMenB Lot1</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="B2">
          <title>rMenB Lot2</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="B3">
          <title>rMenB Lot3</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="B4">
          <title>Routine</title>
          <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
        </group>
        <group group_id="B5">
          <title>MenC+ Routine</title>
          <description>Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="833"/>
                <measurement group_id="B2" value="828"/>
                <measurement group_id="B3" value="820"/>
                <measurement group_id="B4" value="659"/>
                <measurement group_id="B5" value="490"/>
                <measurement group_id="B6" value="3630"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.8" spread="9.5"/>
                <measurement group_id="B2" value="74.1" spread="9.6"/>
                <measurement group_id="B3" value="73.3" spread="9.4"/>
                <measurement group_id="B4" value="74.7" spread="9.3"/>
                <measurement group_id="B5" value="70.6" spread="9.7"/>
                <measurement group_id="B6" value="73.5" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="403"/>
                <measurement group_id="B2" value="400"/>
                <measurement group_id="B3" value="416"/>
                <measurement group_id="B4" value="318"/>
                <measurement group_id="B5" value="234"/>
                <measurement group_id="B6" value="1771"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="430"/>
                <measurement group_id="B2" value="428"/>
                <measurement group_id="B3" value="404"/>
                <measurement group_id="B4" value="341"/>
                <measurement group_id="B5" value="256"/>
                <measurement group_id="B6" value="1859"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination</title>
        <description>The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).</description>
        <time_frame>one month after the third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on Per protocol (PP)population - All subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB Lot1</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>rMenB Lot2</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O3">
            <title>rMenB Lot3</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="386"/>
                  <measurement group_id="O2" value="380"/>
                  <measurement group_id="O3" value="394"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination</title>
            <description>The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>44/76-SL strain (Baseline) (N= 383, 379, 394)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.21" lower_limit="1.14" upper_limit="1.29"/>
                  <measurement group_id="O2" value="1.19" lower_limit="1.12" upper_limit="1.27"/>
                  <measurement group_id="O3" value="1.19" lower_limit="1.12" upper_limit="1.27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>one month after 3rd vaccination (N=384, 377, 388)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87" lower_limit="80" upper_limit="95"/>
                  <measurement group_id="O2" value="98" lower_limit="90" upper_limit="106"/>
                  <measurement group_id="O3" value="85" lower_limit="78" upper_limit="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5/99 strain (Baseline) (N= 385, 379, 390)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.21" lower_limit="1.14" upper_limit="1.3"/>
                  <measurement group_id="O2" value="1.2" lower_limit="1.12" upper_limit="1.28"/>
                  <measurement group_id="O3" value="1.21" lower_limit="1.13" upper_limit="1.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>one month after 3rd vaccination (N = 384,380,388)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="598" lower_limit="550" upper_limit="651"/>
                  <measurement group_id="O2" value="681" lower_limit="626" upper_limit="741"/>
                  <measurement group_id="O3" value="607" lower_limit="558" upper_limit="661"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NZ98/254 strain (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.03" lower_limit="1" upper_limit="1.06"/>
                  <measurement group_id="O2" value="1.06" lower_limit="1.03" upper_limit="1.1"/>
                  <measurement group_id="O3" value="1.04" lower_limit="1" upper_limit="1.07"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>one month after 3rd vaccination (N= 385, 378, 389)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15" lower_limit="13" upper_limit="17"/>
                  <measurement group_id="O2" value="14" lower_limit="12" upper_limit="16"/>
                  <measurement group_id="O3" value="15" lower_limit="14" upper_limit="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot1 to rMenB Lot2 for 44/76-SL strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot1 and rMenB Lot2 would be equivalent for 44/76-SL strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot1 to rMenB Lot3 for 44/76-SL strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot1 and rMenB Lot3 would be equivalent for 44/76-SL strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot2 to rMenB Lot3 for 44/76-SL strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot2 and rMenB Lot3 would be equivalent for 44/76-SL strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot1 to rMenB Lot2 for 5/99 strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot1 and rMenB Lot2 would be equivalent for 5/99 strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot1 to rMenB Lot3 for 5/99 strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot1 and rMenB Lot3 would be equivalent for 5/99 strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot2 to rMenB Lot3 for 5/99 strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot2 and rMenB Lot3 would be equivalent for 5/99 strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot1 to rMenB Lot2 for NZ98/254 strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot1 and rMenB Lot2 would be equivalent for for NZ98/254 strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot1 to rMenB Lot3 for NZ98/254 strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot1 and rMenB Lot3 would be equivalent for for NZ98/254 strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing rMenB Lot2 to rMenB Lot3 for NZ98
/254 strain at one month after the third vaccination was contained within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two sided 95% CIs for the ratio of the hSBA GMT at one month following third vaccination was within this equivalence interval for each of the two co-primary comparisons, rMenB Lot2 and rMenB Lot3 would be equivalent for for NZ98 /254 strain with respect to the immune response to the vaccine lot.</non_inferiority_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)</title>
        <description>The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.</description>
        <time_frame>one month after the third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on PP population - All subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1160"/>
                  <measurement group_id="O2" value="121"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)</title>
            <description>The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>44/76-SL strain (Baseline) (N= 1156, 119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                  <measurement group_id="O2" value="3" lower_limit="1" upper_limit="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=1149, 117)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5/99 strain (Baseline) (N= 1154, 120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                  <measurement group_id="O2" value="7" lower_limit="3" upper_limit="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=1152, 116)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NZ98/254 strain (Baseline) (N=1160, 120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="1" upper_limit="2"/>
                  <measurement group_id="O2" value="1" lower_limit="0.021" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=1152, 121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84" lower_limit="82" upper_limit="86"/>
                  <measurement group_id="O2" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)</title>
        <description>The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.</description>
        <time_frame>1 month after the third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on Per protocol (PP)population - All subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB Lot1</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>rMenB Lot2</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O3">
            <title>rMenB Lot3</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O4">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="386"/>
                  <measurement group_id="O2" value="380"/>
                  <measurement group_id="O3" value="394"/>
                  <measurement group_id="O4" value="121"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)</title>
            <description>The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>44/76-SL Baseline (N= 383,379,394,119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4" lower_limit="2" upper_limit="6"/>
                  <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O3" value="3" lower_limit="2" upper_limit="6"/>
                  <measurement group_id="O4" value="3" lower_limit="1" upper_limit="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=384,377,388,117)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O3" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O4" value="3" lower_limit="1" upper_limit="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5/99 Baseline (N=385,379,390,120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                  <measurement group_id="O2" value="4" lower_limit="3" upper_limit="7"/>
                  <measurement group_id="O3" value="4" lower_limit="2" upper_limit="7"/>
                  <measurement group_id="O4" value="7" lower_limit="3" upper_limit="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=384,380,388,116)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O3" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O4" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NZ 98/254 Baseline (N = 386,380,394,120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                  <measurement group_id="O2" value="2" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O3" value="1" lower_limit="0" upper_limit="2"/>
                  <measurement group_id="O4" value="1" lower_limit="0.021" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=385,378,389,121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84" lower_limit="80" upper_limit="88"/>
                  <measurement group_id="O2" value="81" lower_limit="77" upper_limit="85"/>
                  <measurement group_id="O3" value="85" lower_limit="81" upper_limit="89"/>
                  <measurement group_id="O4" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at one month after the third vaccination, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot1 and rMenB Lot2 would be equivalent for 44/76-SL strain.</non_inferiority_desc>
            <param_type>Vaccines Group Differences</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at 1month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot1 and rMenB Lot3 would be equivalent for 44/76-SL strain.</non_inferiority_desc>
            <param_type>Vaccines Group Differences</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at 1month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot2 and rMenB Lot3 would be equivalent for 44/76-SL strain.</non_inferiority_desc>
            <param_type>Vaccines Group Differences</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at 1month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot1 and rMenB Lot2 would be equivalent for 5/99 strain.</non_inferiority_desc>
            <param_type>Vaccines Group Differences</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at 1month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot1 and rMenB Lot3 would be equivalent for 5/99 strain.</non_inferiority_desc>
            <param_type>Vaccines Group Differences</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at 1month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot2 and rMenB Lot3 would be equivalent for 5/99 strain.</non_inferiority_desc>
            <param_type>Vaccines Group Differences</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentages of subjects with hSBA titers ≥ 1:5 at 1 month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot1 and rMenB Lot2 would be equivalent for NZ98/254 strain.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at 1 month after the third dise, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided 95% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot1 and rMenB Lot3 would be equivalent for NZ 98/254 strain.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The three vaccine lots would be considered equivalent if for each of the three strains and each pair of vaccine lots, the 95% CIs of the differences in the percentage of subjects with hSBA titers ≥ 1:5 at one month after the third dose, were entirely within the interval [-10%, 10%].</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (-10%, 10%). If the two sided (5% CIs of the differences in the percentages of subjects at one month following third vaccination was within this equivalence interval for each of the two comparisons, rMenB Lot2 and rMenB Lot3 would be equivalent for NZ98/254 strain.</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ</title>
        <description>The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.</description>
        <time_frame>1 Month after the third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on Per protocol (PP)population - All subjects who received all the relevant doses of vaccine correctly, and provided evaluable serum samples at the relevant time points, and had no major protocol violation as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3)at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1160"/>
                  <measurement group_id="O2" value="121"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ</title>
            <description>The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>44/76 Strain (Baseline) (N=1156, 119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.15" lower_limit="1.12" upper_limit="1.19"/>
                  <measurement group_id="O2" value="1.12" lower_limit="1.04" upper_limit="1.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=1149, 117)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="87" upper_limit="95"/>
                  <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5/99 Strain (Baseline) (N=1154, 120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.18" lower_limit="1.14" upper_limit="1.22"/>
                  <measurement group_id="O2" value="1.21" lower_limit="1.1" upper_limit="1.33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=1152, 116)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="635" lower_limit="606" upper_limit="665"/>
                  <measurement group_id="O2" value="1.06" lower_limit="0.97" upper_limit="1.17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NZ98/254 (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.05" lower_limit="1.03" upper_limit="1.07"/>
                  <measurement group_id="O2" value="1.01" lower_limit="0.99" upper_limit="1.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N= 1152, 121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14" lower_limit="13" upper_limit="15"/>
                  <measurement group_id="O2" value="1.04" lower_limit="0.98" upper_limit="1.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)</title>
        <description>The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.</description>
        <time_frame>1 month after third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on PP dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB Lot1</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>rMenB Lot2</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O3">
            <title>rMenB Lot3</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O4">
            <title>rMenB All</title>
            <description>Subjects received one injection fo rMenB+OMV NZ (Lot1, or Lot 2, or Lot 3) at 2, 4, and 6months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O5">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="615"/>
                  <measurement group_id="O2" value="600"/>
                  <measurement group_id="O3" value="611"/>
                  <measurement group_id="O4" value="1823"/>
                  <measurement group_id="O5" value="113"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)</title>
            <description>The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline (N= 611,596,611,1818,113)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22" lower_limit="21" upper_limit="23"/>
                  <measurement group_id="O2" value="22" lower_limit="21" upper_limit="22"/>
                  <measurement group_id="O3" value="22" lower_limit="21" upper_limit="23"/>
                  <measurement group_id="O4" value="22" lower_limit="21" upper_limit="22"/>
                  <measurement group_id="O5" value="21" lower_limit="20" upper_limit="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vacc (N= 615,600,608,1823,113)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3149" lower_limit="2960" upper_limit="3352"/>
                  <measurement group_id="O2" value="3484" lower_limit="3270" upper_limit="3712"/>
                  <measurement group_id="O3" value="3103" lower_limit="2915" upper_limit="3304"/>
                  <measurement group_id="O4" value="3370" lower_limit="3270" upper_limit="3472"/>
                  <measurement group_id="O5" value="22" lower_limit="21" upper_limit="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations</title>
        <description>Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.</description>
        <time_frame>1 month after third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on Immunogenicity Routine PP (Pertussis Antigens)</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3)at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="246"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations</title>
            <description>Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FHA (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.98" lower_limit="8.78" upper_limit="11"/>
                  <measurement group_id="O2" value="9.28" lower_limit="8.17" upper_limit="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123" lower_limit="114" upper_limit="133"/>
                  <measurement group_id="O2" value="147" lower_limit="136" upper_limit="158"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pertactin (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.3" lower_limit="5.52" upper_limit="7.17"/>
                  <measurement group_id="O2" value="5.36" lower_limit="4.71" upper_limit="6.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107" lower_limit="97" upper_limit="119"/>
                  <measurement group_id="O2" value="139" lower_limit="126" upper_limit="155"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PT (Baseline)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.82" lower_limit="2.68" upper_limit="2.96"/>
                  <measurement group_id="O2" value="2.82" lower_limit="2.68" upper_limit="2.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vaccination (N= 239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41" lower_limit="37" upper_limit="44"/>
                  <measurement group_id="O2" value="51" lower_limit="46" upper_limit="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the pertussis components (FHA) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after the third vaccination is ≥0.67.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>GMCs (GMCrMenB+OMV NZ lot1+lot2+lot3+InfanrixHexa / GMCInfanrixHexa)</non_inferiority_desc>
            <param_type>Geometric group difference</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the pertussis component (Pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after the third vaccination is ≥0.67.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>GMCs (GMCrMenB+OMV NZ lot1+lot2+lot3+InfanrixHexa / GMCInfanrixHexa)</non_inferiority_desc>
            <param_type>Geometric group difference</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the pertussis components (PT) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after the third vaccination is ≥0.67.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>GMCs (GMCrMenB+OMV NZ lot1+lot2+lot3+InfanrixHexa / GMCInfanrixHexa)</non_inferiority_desc>
            <param_type>Geometric group difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Antibody Response Against the Routine Antigens</title>
        <description>The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(&gt;=1:8). Diptheria and Tetanus: primary endpoint ELISA &gt;=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA&gt;=1.0 IU/mL.
HepB (HBV):primary endpoint ELISA &gt;=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC &gt;=0.35 mcg/ml</description>
        <time_frame>1 Month after third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3)at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="243"/>
                  <measurement group_id="O2" value="246"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With Antibody Response Against the Routine Antigens</title>
            <description>The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(&gt;=1:8). Diptheria and Tetanus: primary endpoint ELISA &gt;=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA&gt;=1.0 IU/mL.
HepB (HBV):primary endpoint ELISA &gt;=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC &gt;=0.35 mcg/ml</description>
            <units>Percentages Of Subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-DiphtheriaToxin ≥0.1IU/mL(Baseline)N=241,246</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38" lower_limit="32" upper_limit="44"/>
                  <measurement group_id="O2" value="38" lower_limit="32" upper_limit="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-DiphtheriaToxin ≥1.0 IU/mL(Baseline)N=241,246</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="1" upper_limit="5"/>
                  <measurement group_id="O2" value="2" lower_limit="1" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80" lower_limit="75" upper_limit="85"/>
                  <measurement group_id="O2" value="86" lower_limit="81" upper_limit="90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-TetanusToxin ≥0.1 IU/mL(Baseline) N=241,246</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93" lower_limit="88" upper_limit="96"/>
                  <measurement group_id="O2" value="95" lower_limit="91" upper_limit="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-Tetanus Toxin ≥1.0 IU/mL(Baseline)N=241, 246</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24" lower_limit="18" upper_limit="30"/>
                  <measurement group_id="O2" value="27" lower_limit="22" upper_limit="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="86" upper_limit="94"/>
                  <measurement group_id="O2" value="95" lower_limit="91" upper_limit="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Polio 1 ≥1:8 (Baseline) (N=245, 246)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75" lower_limit="69" upper_limit="80"/>
                  <measurement group_id="O2" value="72" lower_limit="66" upper_limit="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N= 243, 248)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95" lower_limit="92" upper_limit="98"/>
                  <measurement group_id="O2" value="97" lower_limit="94" upper_limit="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Polio 2 (Baseline) (N= 245, 246)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68" lower_limit="62" upper_limit="74"/>
                  <measurement group_id="O2" value="69" lower_limit="63" upper_limit="74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N= 243, 248)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88" lower_limit="84" upper_limit="92"/>
                  <measurement group_id="O2" value="94" lower_limit="90" upper_limit="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Polio 3 (Baseline) (N= 245, 246)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48" lower_limit="41" upper_limit="54"/>
                  <measurement group_id="O2" value="49" lower_limit="42" upper_limit="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N= 243, 248)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97" lower_limit="94" upper_limit="99"/>
                  <measurement group_id="O2" value="98" lower_limit="95" upper_limit="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HBV ≥10 mIU/mL (Baseline) (N= 241, 248)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22" lower_limit="17" upper_limit="28"/>
                  <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=245, 252)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRP (HIB) ≥ 0.15 μg/mL(Baseline) (N= 241,246)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54" lower_limit="47" upper_limit="60"/>
                  <measurement group_id="O2" value="55" lower_limit="49" upper_limit="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRP (HIB) ≥ 1.0 μg/mL (Baseline) (N=241, 246)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12" lower_limit="9" upper_limit="17"/>
                  <measurement group_id="O2" value="10" lower_limit="7" upper_limit="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N= 239, 244)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79" lower_limit="73" upper_limit="84"/>
                  <measurement group_id="O2" value="79" lower_limit="73" upper_limit="84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC4 ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="2" lower_limit="1" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=242, 243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                  <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC 6B ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14" lower_limit="10" upper_limit="19"/>
                  <measurement group_id="O2" value="16" lower_limit="12" upper_limit="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=242,243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90" lower_limit="85" upper_limit="93"/>
                  <measurement group_id="O2" value="88" lower_limit="83" upper_limit="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC 9V ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4" lower_limit="2" upper_limit="7"/>
                  <measurement group_id="O2" value="3" lower_limit="1" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=242, 243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC 14 ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33" lower_limit="27" upper_limit="39"/>
                  <measurement group_id="O2" value="38" lower_limit="31" upper_limit="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=242, 243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                  <measurement group_id="O2" value="97" lower_limit="94" upper_limit="99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC 18C ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10" lower_limit="7" upper_limit="15"/>
                  <measurement group_id="O2" value="17" lower_limit="12" upper_limit="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=242, 243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC 19F ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20" lower_limit="15" upper_limit="26"/>
                  <measurement group_id="O2" value="21" lower_limit="16" upper_limit="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N=242, 243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96" lower_limit="93" upper_limit="98"/>
                  <measurement group_id="O2" value="96" lower_limit="93" upper_limit="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PnC 23F ≥0.35μg/mL (Baseline) (N=243, 245)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16" lower_limit="12" upper_limit="21"/>
                  <measurement group_id="O2" value="22" lower_limit="17" upper_limit="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after third vaccination (N= 242, 243)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="88" upper_limit="95"/>
                  <measurement group_id="O2" value="95" lower_limit="92" upper_limit="97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the routine infant vaccines, when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age,would be considered non-inferior to that of routine infant vaccines given alone, for diphtheria toxoids antigen, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than or equal to the cut-off level ≥0.1 IU/mL for that antigen.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the routine infant vaccines, when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age, would be considered non-inferior to that of routine infant vaccines given alone, for diphtheria toxoids antigen, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than or equal to the cut-off level ≥1.0 IU/mL for that antigen.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the routine infant vaccines, when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age, would be considered non-inferior to that of routine infant vaccines given alone, for Tetanus toxoids antigen, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than or equal to the cut-off level ≥0.1 IU/mL for that antigen.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the routine infant vaccines, when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age, would be considered non-inferior to that of routine infant vaccines given alone, for Tetanus toxoids antigen, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than or equal to the cut-off level ≥1.0 IU/mL for that antigen.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the polio type 1 of Diphtheria-Tetanus-Acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-HBV-IPV) when given concomitantly with rMenB and Pneumococcal 7-valent conjugate vaccine (PCV7) at 2, 4, and 6 months of age would be considered non-inferior to that of the confidence interval for the difference in the percentage of subjects with NT titers ≥1:8 was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the polio type 2 of Diphtheria-Tetanus-Acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-HBVIPV) when given concomitantly with rMenB and Pneumococcal 7-valent conjugate vaccine (PCV7) at 2, 4, and 6 months of age would be considered non-inferior to that of the confidence interval for the difference in the percentage of subjects with NT titers ≥1:8 was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the polio type 3 of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 at 2,4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two sided 95% confidence interval for the difference in the percentage of subjects with NT titers ≥1:8 was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the hepatitis B surface antigen component of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 vaccine at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two sided 95% confidence interval for the difference in the percentage of subjects with NT ≥10.0 mIU/ml was greater than -10%</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>percentage group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the PRP-Hib component of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 vaccine at 2, 4, and 6 months of age would be considered non-inferiority that of the routine vaccinations given alone, if the lower limit of the two sided 95% confidence interval for the difference in the percentage of subjects with Hib capsular polysaccharide (PRP) antibody response greater than the protective cutoff of ≥0.15 μg/mL was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the PRP-Hib component of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 vaccine at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two sided 95% confidence interval for the difference in the percentage of subjects with Hib capsular polysaccharide (PRP) antibody response greater than the protective cutoff of ≥1.0 μg/mL was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>vaccine group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 when given concomitantly with rMenB and DTPa-HBV-IPV at 2, 4 and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% confidence interval for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL was, for the pneumococcal antigen PnC4.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>percentage group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 when given concomitantly with rMenB and DTPa-HBV-IPV at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL, was, for PnC 6B antigen greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 when given concomitantly with rMenB and DTPa_HBV-IPV vaccine at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two sided 95% CI for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL, was, for PnC 9V, greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 vaccine when given concomitantly with rMenB and DTPa-HBV-IPV at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL, was, for PnC14 antigen, greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 when given concomitantly with rMenB and DTPa-HBV-IPV vaccine at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL, was, for PnC 18C antigen greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 when given concomitantly with rMenB and DTPa-HBV-IPV vaccine at 2, 4 and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL, was for PnC 19F antigen, greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the 7 components of PCV7 when given concomitantly with rMenB and DTPa-HBV-IPV vaccine at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response greater than the cutoff of ≥0.35 μg/mL, was for PnC 23F antigen, greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens</title>
        <description>Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).</description>
        <time_frame>5 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on PP dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3)at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="243"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens</title>
            <description>Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).</description>
            <units>Percentages of Subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FHA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84" lower_limit="79" upper_limit="88"/>
                  <measurement group_id="O2" value="87" lower_limit="82" upper_limit="91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pertactin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79" lower_limit="73" upper_limit="84"/>
                  <measurement group_id="O2" value="88" lower_limit="84" upper_limit="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="88" upper_limit="95"/>
                  <measurement group_id="O2" value="95" lower_limit="91" upper_limit="97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the FHA antigen of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 vaccine at 2, 4 and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the Pertactin antigen of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 at 2, 4 and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16</ci_lower_limit>
            <ci_upper_limit>-3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of the PT antigen of DTPa-HBV-IPV vaccine given concomitantly with rMenB and PCV7 vaccine at 2, 4, and 6 months of age would be considered non-inferior to that of the routine vaccinations given alone if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects was greater than -10%.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>{PConcomitant Vaccine +rMenB+OMV NZ lot1+lot2+lot3 minus PConcomitant Vaccine}</non_inferiority_desc>
            <param_type>Percentage group difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination</title>
        <description>Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.</description>
        <time_frame>1 Month after third vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on PP dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB Lot1</title>
            <description>Subjects received one injection of rMenB+OMV NZ(Lot1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>rMenB Lot2</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O3">
            <title>rMenB Lot3</title>
            <description>Subjects received one injection of rMenB+OMV NZ(Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O4">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot2, or Lot3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O5">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="370"/>
                  <measurement group_id="O2" value="359"/>
                  <measurement group_id="O3" value="376"/>
                  <measurement group_id="O4" value="1102"/>
                  <measurement group_id="O5" value="114"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination</title>
            <description>Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.</description>
            <units>Percentages of Subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>44/76-SL (N=369, 356, 373, 1098, 111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O3" value="98" lower_limit="97" upper_limit="99"/>
                  <measurement group_id="O4" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O5" value="1" lower_limit="0.023" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5/99 (N=370, 359, 369, 1098, 111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O3" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O4" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O5" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NZ98/254 (N=369, 357, 376, 1102, 114)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70" lower_limit="66" upper_limit="75"/>
                  <measurement group_id="O2" value="69" lower_limit="64" upper_limit="74"/>
                  <measurement group_id="O3" value="75" lower_limit="70" upper_limit="79"/>
                  <measurement group_id="O4" value="71" lower_limit="69" upper_limit="74"/>
                  <measurement group_id="O5" value="1" lower_limit="0.022" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA Titers ≥1:8</title>
        <description>Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.</description>
        <time_frame>1 month after third vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis was done on PP population</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB Lot1</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>rMenB Lot2</title>
            <description>Subjects received one injection of rMenB+OMV NZ(Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O3">
            <title>rMenB Lot3</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O4">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3)at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O5">
            <title>Routine</title>
            <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="386"/>
                  <measurement group_id="O2" value="379"/>
                  <measurement group_id="O3" value="394"/>
                  <measurement group_id="O4" value="1156"/>
                  <measurement group_id="O5" value="119"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects With hSBA Titers ≥1:8</title>
            <description>Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>44/76-SL (Baseline)N=383,379,394,1156,119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  <measurement group_id="O3" value="2" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O4" value="2" lower_limit="1" upper_limit="3"/>
                  <measurement group_id="O5" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vacc(N=384, 377,388,1149, 117)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O3" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O4" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O5" value="1" lower_limit="0.022" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5/99 (Baseline) (N=385, 379, 390, 1154, 120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3" lower_limit="1" upper_limit="5"/>
                  <measurement group_id="O2" value="3" lower_limit="1" upper_limit="5"/>
                  <measurement group_id="O3" value="2" lower_limit="1" upper_limit="4"/>
                  <measurement group_id="O4" value="3" lower_limit="2" upper_limit="4"/>
                  <measurement group_id="O5" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vacc(N=384, 380, 388,1152, 116)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O3" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O4" value="100" lower_limit="99" upper_limit="100"/>
                  <measurement group_id="O5" value="2" lower_limit="0" upper_limit="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NZ98/254 (Baseline) (N=386, 380, 394, 1160, 120)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.063" upper_limit="2"/>
                  <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="1"/>
                  <measurement group_id="O4" value="1" lower_limit="0" upper_limit="1"/>
                  <measurement group_id="O5" value="0" lower_limit="0" upper_limit="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Month after 3rd vacc (N=385, 378, 389,1152, 121)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70" lower_limit="66" upper_limit="75"/>
                  <measurement group_id="O2" value="70" lower_limit="65" upper_limit="74"/>
                  <measurement group_id="O3" value="75" lower_limit="70" upper_limit="79"/>
                  <measurement group_id="O4" value="72" lower_limit="69" upper_limit="74"/>
                  <measurement group_id="O5" value="1" lower_limit="0.021" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine</title>
        <description>The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.</description>
        <time_frame>upto 7 days after any vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis was done on safety subset population - all subjects enrolled who received study vaccination and provided post-baseline safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>rMenB All</title>
            <description>Subjects received one injection of rMenB+OMV NZ (Lot 1, or Lot 2, or Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
          </group>
          <group group_id="O2">
            <title>MenC+Routine</title>
            <description>Subjects received the routinely administered infant vaccines and MenC vaccine at 2, 4 and 6 months of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2479"/>
                  <measurement group_id="O2" value="490"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine</title>
            <description>The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2388"/>
                  <measurement group_id="O2" value="443"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site tenderness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2147"/>
                  <measurement group_id="O2" value="266"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2049"/>
                  <measurement group_id="O2" value="261"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1908"/>
                  <measurement group_id="O2" value="227"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1174"/>
                  <measurement group_id="O2" value="84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2450"/>
                  <measurement group_id="O2" value="459"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in Eating Habits</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1787"/>
                  <measurement group_id="O2" value="257"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2159"/>
                  <measurement group_id="O2" value="353"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="662"/>
                  <measurement group_id="O2" value="116"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1086"/>
                  <measurement group_id="O2" value="164"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2296"/>
                  <measurement group_id="O2" value="370"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Unusual Crying</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2109"/>
                  <measurement group_id="O2" value="352"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever &gt;= 38.5C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1912"/>
                  <measurement group_id="O2" value="228"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Others</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2302"/>
                  <measurement group_id="O2" value="325"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medical Attend. Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Analg. Antipyretic Med.Used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2302"/>
                  <measurement group_id="O2" value="325"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Antipyretic Med.Used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2240"/>
                  <measurement group_id="O2" value="314"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All serious adverse events and medically attended adverse events are collected from Day 8 after each vaccination to next vaccination or to 30 days after the last vaccination.</time_frame>
      <desc>Of a total of 3630 enrolled subjects, 3629 received at least one vaccination and were included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>rMenB Lot1</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="E2">
          <title>rMenB Lot2</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="E3">
          <title>rMenB Lot3</title>
          <description>Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.</description>
        </group>
        <group group_id="E4">
          <title>Routine</title>
          <description>Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.</description>
        </group>
        <group group_id="E5">
          <title>MenC+Routine</title>
          <description>Subjects received the routinely administered infant vaccines and MenC vaccine at 2, 4 and 6 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Aplasia pure red cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Congenital Coronary Artery Malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Faciodigitogenital Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gnathoschisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Microcephaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Thalassaemia Beta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Infantile Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Intusscusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (17.1)">Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Exanthema Subitum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Febrile Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pseudocroup</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (17.1)">H1N1 Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Foregin body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Feeding disorder or infancy or early childhood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Premature closure of cranial sutures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (17.1)">Generalised Tonic-Clonic Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Infantile spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath Holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Decreased activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Eczema Nummular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Labial frenectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="827" subjects_at_risk="832"/>
                <counts group_id="E2" subjects_affected="825" subjects_at_risk="828"/>
                <counts group_id="E3" subjects_affected="817" subjects_at_risk="820"/>
                <counts group_id="E4" subjects_affected="652" subjects_at_risk="659"/>
                <counts group_id="E5" subjects_affected="482" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="607" subjects_affected="370" subjects_at_risk="832"/>
                <counts group_id="E2" events="632" subjects_affected="380" subjects_at_risk="828"/>
                <counts group_id="E3" events="624" subjects_affected="368" subjects_at_risk="820"/>
                <counts group_id="E4" events="358" subjects_affected="225" subjects_at_risk="659"/>
                <counts group_id="E5" events="286" subjects_affected="168" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="315" subjects_affected="217" subjects_at_risk="832"/>
                <counts group_id="E2" events="329" subjects_affected="234" subjects_at_risk="828"/>
                <counts group_id="E3" events="317" subjects_affected="216" subjects_at_risk="820"/>
                <counts group_id="E4" events="149" subjects_affected="108" subjects_at_risk="659"/>
                <counts group_id="E5" events="178" subjects_affected="120" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1740" subjects_affected="714" subjects_at_risk="832"/>
                <counts group_id="E2" events="1750" subjects_affected="711" subjects_at_risk="828"/>
                <counts group_id="E3" events="1693" subjects_affected="685" subjects_at_risk="820"/>
                <counts group_id="E4" events="822" subjects_affected="424" subjects_at_risk="659"/>
                <counts group_id="E5" events="752" subjects_affected="352" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="4171" subjects_affected="729" subjects_at_risk="832"/>
                <counts group_id="E2" events="4135" subjects_affected="733" subjects_at_risk="828"/>
                <counts group_id="E3" events="4034" subjects_affected="704" subjects_at_risk="820"/>
                <counts group_id="E4" events="1792" subjects_affected="497" subjects_at_risk="659"/>
                <counts group_id="E5" events="1788" subjects_affected="385" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="4024" subjects_affected="692" subjects_at_risk="832"/>
                <counts group_id="E2" events="3915" subjects_affected="680" subjects_at_risk="828"/>
                <counts group_id="E3" events="3926" subjects_affected="664" subjects_at_risk="820"/>
                <counts group_id="E4" events="1741" subjects_affected="452" subjects_at_risk="659"/>
                <counts group_id="E5" events="1761" subjects_affected="390" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="4472" subjects_affected="736" subjects_at_risk="832"/>
                <counts group_id="E2" events="4497" subjects_affected="736" subjects_at_risk="828"/>
                <counts group_id="E3" events="4541" subjects_affected="728" subjects_at_risk="820"/>
                <counts group_id="E4" events="1364" subjects_affected="415" subjects_at_risk="659"/>
                <counts group_id="E5" events="1615" subjects_affected="358" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1683" subjects_affected="440" subjects_at_risk="832"/>
                <counts group_id="E2" events="1688" subjects_affected="466" subjects_at_risk="828"/>
                <counts group_id="E3" events="1743" subjects_affected="436" subjects_at_risk="820"/>
                <counts group_id="E4" events="653" subjects_affected="254" subjects_at_risk="659"/>
                <counts group_id="E5" events="519" subjects_affected="184" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1344" subjects_affected="656" subjects_at_risk="832"/>
                <counts group_id="E2" events="1338" subjects_affected="646" subjects_at_risk="828"/>
                <counts group_id="E3" events="1332" subjects_affected="643" subjects_at_risk="820"/>
                <counts group_id="E4" events="493" subjects_affected="319" subjects_at_risk="659"/>
                <counts group_id="E5" events="425" subjects_affected="248" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" events="76" subjects_affected="42" subjects_at_risk="832"/>
                <counts group_id="E2" events="60" subjects_affected="30" subjects_at_risk="828"/>
                <counts group_id="E3" events="74" subjects_affected="38" subjects_at_risk="820"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="659"/>
                <counts group_id="E5" events="105" subjects_affected="51" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="129" subjects_affected="102" subjects_at_risk="832"/>
                <counts group_id="E2" events="132" subjects_affected="98" subjects_at_risk="828"/>
                <counts group_id="E3" events="123" subjects_affected="94" subjects_at_risk="820"/>
                <counts group_id="E4" events="125" subjects_affected="97" subjects_at_risk="659"/>
                <counts group_id="E5" events="80" subjects_affected="59" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="91" subjects_affected="74" subjects_at_risk="832"/>
                <counts group_id="E2" events="100" subjects_affected="80" subjects_at_risk="828"/>
                <counts group_id="E3" events="91" subjects_affected="77" subjects_at_risk="820"/>
                <counts group_id="E4" events="66" subjects_affected="60" subjects_at_risk="659"/>
                <counts group_id="E5" events="19" subjects_affected="16" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="119" subjects_affected="86" subjects_at_risk="832"/>
                <counts group_id="E2" events="106" subjects_affected="70" subjects_at_risk="828"/>
                <counts group_id="E3" events="85" subjects_affected="57" subjects_at_risk="820"/>
                <counts group_id="E4" events="91" subjects_affected="59" subjects_at_risk="659"/>
                <counts group_id="E5" events="38" subjects_affected="26" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="832"/>
                <counts group_id="E2" events="47" subjects_affected="47" subjects_at_risk="828"/>
                <counts group_id="E3" events="46" subjects_affected="46" subjects_at_risk="820"/>
                <counts group_id="E4" events="38" subjects_affected="38" subjects_at_risk="659"/>
                <counts group_id="E5" events="21" subjects_affected="21" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="832"/>
                <counts group_id="E2" events="51" subjects_affected="47" subjects_at_risk="828"/>
                <counts group_id="E3" events="41" subjects_affected="38" subjects_at_risk="820"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="659"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="97" subjects_affected="78" subjects_at_risk="832"/>
                <counts group_id="E2" events="108" subjects_affected="79" subjects_at_risk="828"/>
                <counts group_id="E3" events="106" subjects_affected="81" subjects_at_risk="820"/>
                <counts group_id="E4" events="107" subjects_affected="73" subjects_at_risk="659"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="256" subjects_affected="152" subjects_at_risk="832"/>
                <counts group_id="E2" events="267" subjects_affected="145" subjects_at_risk="828"/>
                <counts group_id="E3" events="284" subjects_affected="156" subjects_at_risk="820"/>
                <counts group_id="E4" events="229" subjects_affected="124" subjects_at_risk="659"/>
                <counts group_id="E5" events="38" subjects_affected="28" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="90" subjects_affected="78" subjects_at_risk="832"/>
                <counts group_id="E2" events="120" subjects_affected="99" subjects_at_risk="828"/>
                <counts group_id="E3" events="66" subjects_affected="58" subjects_at_risk="820"/>
                <counts group_id="E4" events="84" subjects_affected="63" subjects_at_risk="659"/>
                <counts group_id="E5" events="33" subjects_affected="30" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="190" subjects_affected="142" subjects_at_risk="832"/>
                <counts group_id="E2" events="172" subjects_affected="126" subjects_at_risk="828"/>
                <counts group_id="E3" events="175" subjects_affected="133" subjects_at_risk="820"/>
                <counts group_id="E4" events="124" subjects_affected="94" subjects_at_risk="659"/>
                <counts group_id="E5" events="59" subjects_affected="47" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1657" subjects_affected="714" subjects_at_risk="832"/>
                <counts group_id="E2" events="1684" subjects_affected="729" subjects_at_risk="828"/>
                <counts group_id="E3" events="1624" subjects_affected="716" subjects_at_risk="820"/>
                <counts group_id="E4" events="914" subjects_affected="476" subjects_at_risk="659"/>
                <counts group_id="E5" events="711" subjects_affected="353" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" events="1152" subjects_affected="588" subjects_at_risk="832"/>
                <counts group_id="E2" events="1223" subjects_affected="603" subjects_at_risk="828"/>
                <counts group_id="E3" events="1211" subjects_affected="596" subjects_at_risk="820"/>
                <counts group_id="E4" events="580" subjects_affected="329" subjects_at_risk="659"/>
                <counts group_id="E5" events="492" subjects_affected="257" subjects_at_risk="490"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2181" subjects_affected="769" subjects_at_risk="832"/>
                <counts group_id="E2" events="2168" subjects_affected="761" subjects_at_risk="828"/>
                <counts group_id="E3" events="2183" subjects_affected="766" subjects_at_risk="820"/>
                <counts group_id="E4" events="1339" subjects_affected="544" subjects_at_risk="659"/>
                <counts group_id="E5" events="877" subjects_affected="370" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="66" subjects_affected="59" subjects_at_risk="832"/>
                <counts group_id="E2" events="66" subjects_affected="58" subjects_at_risk="828"/>
                <counts group_id="E3" events="69" subjects_affected="60" subjects_at_risk="820"/>
                <counts group_id="E4" events="48" subjects_affected="43" subjects_at_risk="659"/>
                <counts group_id="E5" events="51" subjects_affected="40" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="180" subjects_affected="121" subjects_at_risk="832"/>
                <counts group_id="E2" events="168" subjects_affected="119" subjects_at_risk="828"/>
                <counts group_id="E3" events="147" subjects_affected="110" subjects_at_risk="820"/>
                <counts group_id="E4" events="116" subjects_affected="88" subjects_at_risk="659"/>
                <counts group_id="E5" events="79" subjects_affected="50" subjects_at_risk="490"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
